Spike Protein News and Research

RSS

Ad26.COV2.S vaccine effectiveness for preventing COVID-19

A group of multi-national researchers has expanded on previous research to conduct a preliminary evaluation of the effectiveness of the Ad26.COV2.S vaccine via HER data.

8 Nov 2021

Study finds SARS-CoV-2 infection of endothelial cells unlikely

Researchers from the University of Queensland have investigated whether infection of endothelial cells with SARS-CoV-2 is possible.

8 Nov 2021

Researchers explain why decaying SARS-CoV-2 antibodies in blood are not a problem after vaccination

A new study published in the preprint bioRxiv* server suggests vaccination helps to inflate the number of somatic hypermutations acquired by B cells. The increase in somatic hypermutations allows for an accumulation of highly matured bone marrow plasma cells.

8 Nov 2021

Rapid antibody response induced by mRNA COVID vaccines in mice

A new study posted in the bioRxiv* preprint server used mouse models to investigate how mRNA vaccines elicit a rapid antibody response. Their findings show two different mRNA vaccines successfully boost antibody levels — IL-5, IL-6, and MCP-1 —5 days after administration.

7 Nov 2021

New type of COVID vaccine potentially easier to produce and does not need refrigeration

Currently available COVID vaccines require cold storage and sophisticated manufacturing capacity, which makes it difficult to produce and distribute them widely, especially in less developed countries.

6 Nov 2021

Study uncovers a process in cells that may limit infectivity of SARS-CoV-2

Scientists at the National Institutes of Health have found that a process in cells may limit infectivity of SARS-CoV-2, and that mutations in the alpha and delta variants overcome this effect, potentially boosting the virus's ability to spread.

6 Nov 2021

Cuba reports 92.4 percent efficacy for 3 dose SOBERANA 02 COVID-19 vaccine

A new study describes the results of the safety and efficacy phase trials of a new COVID-19 vaccine from Cuba.

4 Nov 2021

Aptamer Group and DeepVerge expand partnership for Optimer-enabled wastewater monitoring

Aptamer Group Ltd., the developer of Optimer® binders to enable innovation in the life science industry, is pleased to announce the expansion of its existing partnership with DeepVerge PLC.

4 Nov 2021

Genomic characterization of SARS-CoV-2 gamma variant in Brazil

In this study, researchers describe the full-length SARS-CoV-2 genomes of 44 clinical samples from Amazonas, Brazil.

4 Nov 2021

Identification of novel SARS-CoV-2 alpha variant sub-lineage in Europe

Scientists from Germany have recently identified a new sub-lineage of the alpha variant of SARS-CoV-2 in some European countries.

4 Nov 2021

Cross-reactive immunity against coronaviruses

Researchers review the heterologous immunity to coronaviruses and the extent of immune cross-reactivity against SARS-CoV-2.

3 Nov 2021

Pre-clinical follow-up study boosting with original formulation and next generation INO-4802 SARS-CoV-2 vaccine candidate

Researchers describe the antibody-inducing effects of DNA-based synthetic vaccines INO-4800 and INO-4802 against SARS-CoV-2 in non-human primates.

3 Nov 2021

SARS-CoV-2 neutralizing antibodies discovered in a 20-year-old human antibody library

In an article published in the open-access journal Advance Engineering, a multinational team of researchers reported the selection and characterization of 3 potent SARS-CoV-2 antibodies - S-E6, S-B8, and S-D4 - from a pre-COVID-19 human combinatorial antibody library that was established 20 years ago.

3 Nov 2021

Dutch study compares mRNA vaccines to vector-based vaccines for COVID-19

An overview of the PIENTER-Corona (PiCo) study, which is a Dutch nationwide efficacy comparison study on four different COVID-19 vaccines.

2 Nov 2021

The pros and cons of a COVID-19 vaccine booster

The authors provide an overview of current literature available to assess the need for COVID-19 vaccine booster doses and their potential target population.

2 Nov 2021

Humoral and cell-mediated immunity six months post BNT162b2 vaccination

A recent study has evaluated vaccine-induced humoral and cellular immunity against SARS-CoV-2 six months post BNT162b2 (Pfizer-BioNTech) vaccination.

2 Nov 2021

Trends in SARS-CoV-2 seroprevalence in Massachusetts

A new study reported findings from a retrospective, de-identified and systematic survey of SARS-CoV-2 seroprevalence among childbearing women in Massachusetts.

2 Nov 2021

Isolation of potent neutralizing monoclonal antibodies using nanoparticles displaying SARS-CoV-2 S glycoprotein

A new study aimed to identify several potent neutralizing RBD-directed and NTD-directed mAbs that used a nanoparticle displaying the S glycoprotein to capture SARS-CoV-2-specific B cells.

2 Nov 2021

Identification of common genes in COVID-19 and COPD

Based on protein-protein interactions, the paper shows the presence of ten genes that overlap between the two illnesses, also shared by several other deadly and debilitating diseases.

2 Nov 2021

SARS-CoV-2 variants neutralized by camel nanobodies

Researchers from the US recently isolated two VHH nanobodies - 7A3 and 8A2 - from dromedary camels (Camelus dromedaries) using phage display. These nanobodies were found to have a high affinity for the spike RBD and broad neutralization abilities against SARS-CoV-2 and its variants.

2 Nov 2021